Skip to content
OpenCapital
Get started

Hercules Capital HTGC Royalty Contract — Investment cost

Similar metrics at other companies

Innoviva, Inc. logo
INVARoyalty — Capitalized Contract Cost Amortization
$3.46M0.0%
Syndax Pharmaceuticals logo
SNDXRoyalty expense
$11.85M+47.2%
HTF
HTFLRoyalty expense
$568K+37.2%
Ligand Pharmaceuticals logo
LGNDAccrued purchases of financial royalty assets
$0—
Ondas, Inc. logo
ONDSRoyalty Expense
$85.5K+23.5%
HTF
HTFLRoyalty Expense
$568K+37.2%

Other financials

Income statement

See full
Net income$42.5M-15.6%
EPS (diluted)$0.23-20.7%

Balance sheet

See full
Cash & equivalents$44.9M-17.3%
Total debt$2.6B+28.1%
Total equity$2.2B+11.3%
Total assets$4.8B+19.7%

Cash flow

See full
Operating cash flow-$230.6M-3.8%
CapEx$19.0K+138%
Free cash flow-$230.7M-3.8%

Valuation

See full
Market cap$2.83B-18.4%

Returns & leverage

See full
Return on equity15.7%+4.3pp
Debt / equity1.1×+0.2×

Where this comes from

Reported directly by Hercules Capital in its filing.

Tagged under the XBRL concept us-gaap:InvestmentOwnedAtCost.

The official record: Hercules Capital’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Hercules Capital's royalty contract — investment cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Hercules Capital's royalty contract — investment cost?
Hercules Capital (HTGC) reported royalty contract — investment cost of $11.5M in Q1 2026.
How has Hercules Capital's royalty contract — investment cost changed year-over-year?
Hercules Capital's royalty contract — investment cost decreased by 3.4% year-over-year, from $11.9M to $11.5M.
What does royalty contract — investment cost mean?
This metric represents the total historical acquisition cost of royalty-based financing agreements within the company's investment portfolio. It serves as the baseline capital deployed into contracts where the company receives a percentage of future revenues or product sales from portfolio companies. Tracking this cost provides insight into the initial capital allocation strategy for non-traditional debt instruments.